Profiling the HLA-II Immunopeptidome of SARS-CoV-2 Spike Glycoprotein Using Mass Spectrometry.
***Available Now!*** In this webinar, Mike Knierman, Eli Lilly, will discuss the use of mass spectrometry to identify unique sequences from SARS-CoV-2 spike glycoprotein extracellular domain in a complex with human leukocyte antigen class II molecules on antigen presenting cells from healthy donors. This work exemplifies the value-add of mass spectrometry in vaccine development. *On Demand until March 30, 2022*
Register Free: https://www.biopharminternational.com/bp_w/glycoprotein_mass_spec
Event Overview:
In this webinar, learn how mass spectrometry has been used to identify more than 500 unique sequences from SARS-CoV-2 spike glycoprotein extracellular domain in a complex with human leukocyte antigen class II molecules on antigen presenting cells from a panel of healthy donors.This work by researchers at Eli Lilly and Co. represents the most precise and comprehensive HLA-II immunopeptidomic investigation with SARS-CoV-2 spike glycoprotein and allows for detailed analysis of features, which may aid crucial vaccine development.
Key Learning Objectives:
- How to use mass spectrometry-based approaches to examine immune response in viral infections
- Considerations for successful immunopeptidomics work
- Application of chosen approach in developing novel subunit or nucleic acid-based vaccines.
Speaker:
Michael Knierman, Senior Research Scientist, Eli Lilly and Co.
Sponsor: Thermo Fisher Scientific
Register Free: https://www.biopharminternational.com/bp_w/glycoprotein_mass_spec
